Publication:
Bcg vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies

dc.contributor.authorMarciano, Beatriz E.
dc.contributor.authorHuang, Chiung-Yu
dc.contributor.authorJoshi, Gyan
dc.contributor.authorRezaei, Nima
dc.contributor.authorCarvalho, Beatriz Costa
dc.contributor.authorAllwood, Zoe
dc.contributor.authorIkinciogullari, Aydan
dc.contributor.authorReda, Shereen M.
dc.contributor.authorGennery, Andrew
dc.contributor.authorThon, Vojtech
dc.contributor.authorEspinosa-Rosales, Francisco
dc.contributor.authorAl-Herz, Waleed
dc.contributor.authorPorras, Oscar
dc.contributor.authorShcherbina, Anna
dc.contributor.authorSzaflarska, Anna
dc.contributor.authorKılıç, Şebnem
dc.contributor.authorFranco, Jose L.
dc.contributor.authorGomez Raccio, Andrea C.
dc.contributor.authorRoxo, Persio, Jr.
dc.contributor.authorEsteves, Isabel
dc.contributor.authorGalal, Nermeen
dc.contributor.authorGrumach, Anete Sevciovic
dc.contributor.authorAl-Tamemi, Salem
dc.contributor.authorYıldıran, Alişan
dc.contributor.authorOrellana, Julio C.
dc.contributor.authorYamada, Masafumi
dc.contributor.authorMorio, Tomohiro
dc.contributor.authorLiberatore, Diana
dc.contributor.authorOhtsuka, Yoshitoshi
dc.contributor.authorLau, Yu-Lung
dc.contributor.authorNishikomori, Ryuta
dc.contributor.authorTorres-Lozano, Carlos
dc.contributor.authorMazzucchelli, Juliana T. L.
dc.contributor.authorVilela, Maria M. S.
dc.contributor.authorTavares, Fabiola S.
dc.contributor.authorCunha, Luciana
dc.contributor.authorPinto, Jorge A.
dc.contributor.authorEspinosa-Padilla, Sara E.
dc.contributor.authorHernandez-Nieto, Leticia
dc.contributor.authorElfeky, Reem A.
dc.contributor.authorAriga, Tadashi
dc.contributor.authorToshio, Heike
dc.contributor.authorDoğu, Figen
dc.contributor.authorCipe, Funda
dc.contributor.authorFormankova, Renata
dc.contributor.authorEnriqueta Nunez-Nunez, M.
dc.contributor.authorBezrodnik, Liliana
dc.contributor.authorMarques, Jose Goncalo
dc.contributor.authorPereira, Maria I.
dc.contributor.authorListello, Viviana
dc.contributor.authorSlatter, Mary A.
dc.contributor.authorNademi, Zohreh
dc.contributor.authorKowalczyk, Danuta
dc.contributor.authorFleisher, Thomas A.
dc.contributor.authorDavies, Graham
dc.contributor.authorNeven, Benedicte
dc.contributor.authorRosenzweig, Sergio D.
dc.contributor.buuauthorKILIÇ GÜLTEKİN, SARA ŞEBNEM
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatrik İmmünoloji Bilim Dalı.
dc.contributor.researcheridAAH-1658-2021
dc.date.accessioned2024-08-15T10:33:22Z
dc.date.available2024-08-15T10:33:22Z
dc.date.issued2014-04-01
dc.description.abstractBackground: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected.Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID.Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed.Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (<= 3 1 month) showed an increased prevalence of complications (P = 5.006) and death caused by BCG-associated complications (P < .0001). The odds of experiencing complications among patients with T-cell numbers of 250/mu L or less at diagnosis was 2.1 times higher (95% CI, 1.4-3.4 times higher; P = .001) than among those with T-cell numbers of greater than 250/mL. BCG-associated complications were reported in 2 of 78 patients who received antimycobacterial therapy while asymptomatic, and no deaths caused by BCG-associated complications occurred in this group. In contrast, 46 BCG-associated deaths were reported among 160 patients treated with antimycobacterial therapy for a symptomatic BCG infection (P < .0001).Conclusions: BCG vaccine has a very high rate of complications in patients with SCID, which increase morbidity and mortality rates. Until safer and more efficient antituberculosis vaccines become available, delay in BCG vaccination should be considered to protect highly vulnerable populations from preventable complications.
dc.description.sponsorshipIntramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Disease
dc.description.sponsorshipEuropean Community 201549 (EURO-PADnet HEALTH-F2-2008-201549)
dc.description.sponsorshipTehran University Med Sci
dc.description.sponsorshipAmerican Academy of Allergy, Asthma & Immunology (AAAAI) Young Investigator Award
dc.description.sponsorshipEURO-PADnet HEALTH F2-2008-201549
dc.description.sponsorshipBaxter
dc.description.sponsorshipKedrion
dc.description.sponsorshipGrifols
dc.description.sponsorshipSHIRE
dc.description.sponsorshipCSL
dc.description.sponsorshipJapan Science & Technology Agency (JST)
dc.description.sponsorshipMinistry of Education, Culture, and Sport
dc.description.sponsorshipMinistry of Health, Labour and Welfare, Japan
dc.description.sponsorshipAbbVie
dc.description.sponsorshipCSL Behring
dc.description.sponsorshipChugai Pharmaceutical
dc.description.sponsorshipMeiji Pharmaceuticals
dc.description.sponsorshipTeijin Pharma
dc.description.sponsorshipToray Medical
dc.description.sponsorshipInPractice
dc.description.sponsorshipUpToDate
dc.identifier.doi10.1016/j.jaci.2014.02.028
dc.identifier.endpage1141
dc.identifier.issn0091-6749
dc.identifier.issue4
dc.identifier.startpage1134
dc.identifier.urihttps://doi.org/10.1016/j.jaci.2014.02.028
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0091674914002930
dc.identifier.urihttps://hdl.handle.net/11452/44059
dc.identifier.volume133
dc.identifier.wos000333531700025
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherMosby-Elsevier
dc.relation.journalJournal of Allergy and Clinical Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBacillus-calmette-guerin
dc.subjectCentral-nervous-system
dc.subjectImmunocompromised children
dc.subjectTuberculous meningitis
dc.subjectVaccines
dc.subjectPrimary immunodeficiency
dc.subjectSevere combined immunodeficiency
dc.subjectVaccine
dc.subjectBcg
dc.subjectMycobacteria
dc.subjectNewborn screening
dc.subjectHematopoietic stem cell transplant
dc.subjectImmune reconstitution syndrome
dc.subjectAllergy
dc.subjectImmunology
dc.titleBcg vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationcb4f5525-5861-44f7-8234-fc2b376a934d
relation.isAuthorOfPublication.latestForDiscoverycb4f5525-5861-44f7-8234-fc2b376a934d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Kilic_vd_2014.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format

Collections